Sepracor, Inc. (NASDAQ: SEPR), a research-based pharmaceutical company, has focused their efforts on treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products designed to serve large and growing markets. The company’s drug development program has proven its success by yielding a portfolio of pharmaceutical products and candidates. The focus of the program is on treating respiratory and central nervous system (CNS) disorders. For further information, visit the Company’s web site at www.sepracor.com.
- 17 years ago
QualityStocks
Sepracor, Inc. (NASDAQ: SEPR)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Accelerates Upper Kobuk Exploration with Federal Capital Injection
Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include paid advertising.…
-
QualityStocksNewsBreaks – Ucore Rare Metals Inc.’s (TSX.V: UCU) (OTCQX: UURAF) RapidSX(TM) Technology Gains Spotlight Amid Global Rare-Earth Shakeup
Disseminated on behalf of Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) and may include paid advertising.…
-
QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The…